These researchers also reported the early results of an ongoing Phase I clinical trial (NCT03198546) in patients with advanced HCC, pancreatic carcinoma, or ovarian carcinoma who have glypican-3 (GPC3) or mesothelin expression (156). Here, GPC3 is linked to exocrine pancreatic carcinoma.